The book is divided in 4 parts. In the first one, the importance of the analysis of the cardiac dynamics using the ambulatory monitoring technique is presented. The second part contains the description of foundations of impedance cardiography (ICG), the models used to describe the ICG technique and the description of available systems for ambulatory monitoring of cardiac hemodynamics. The third part is devoted to the validation of the ambulatory ICG method, the verification of the quality of long term ICG recordings and the discussion of the limitations of this technique. In the last part, some clinical and research applications of the ICG ambulatory monitoring are presented. The simultaneous recordings of electrocardiogram (ECG) and ICG in the transient cardiac arrhythmia events illustrate the potential applications of that method for quantitative analysis of hemodynamics when the implementation of the stationary methods would be either difficult or not possible to do. The book is followed by references, alphabetical index and appendices containing the technical data of the available systems for portable monitoring of cardiac hemodynamics.

1. The controlled clinical trial - a model for the intricate relationships between clinical medicine and drug research.- 1.1. Introduction.- 1.2. The evolution of the controlled clinical trial (CCT).- 1.3 The implementation of the controlled clinical trial in drug research.- 1.4. Criticism of the classical view of the controlled clinical trial.- 1.5. Conclusions.- 2. The architecture of drug discovery.- 2.1. Introduction.- 1. The discovery process.- 2.2. Current views of drug discovery.- 2.2.1. Basic concepts in drug discovery.- 2.2.2. Basic epistemologies in drug discovery.- 2.3. Scientific discovery from the viewpoint of cognitive science.- 2.4. The drug discovery process revisited.- 2. The representation of knowledge about drugs and diseases.- 2.5. An epistemological analysis of the concept of drug and disease profiles.- 2.5.1. Introduction.- 2.5.2. The concept of drug profile.- 2.5.2.1..The classification of drugs.- 2.5.2.2. Incursion of drug profiles into disease profiles.- 2.5.2.3. The nature of drug characteristics.- 2.5.3. The concept of disease profile.- 2.5.3.1. Disease profiles as pigeon holes of medical knowledge.- 2.5.3.2. The fundamental basis of taxonomy in medicine.- 2.5.3.3. Convergent and divergent forces in clinical taxonomy.- 2.5.3.4. The translation of everyday medical language into the structure of profiles.- 2.5.4. Conclusions.- 3. A set-theoretical model of drug discovery.- 2.6. A definition of the concept of profile in terms of set theory.- 2.6.1. Introduction.- 2.6.2. The first aspect of a profile: membership.- 2.6.3. The second aspect of the concept of profile: values of the disease characteristics.- 2.6.4. The third aspect of the concept of profile: ranking order of characteristics.- 2.6.5. Conclusions.- 2.7. The drug discovery process - a set-theoretical model.- 2.7.1. Introduction.- 2.7.2. A naive definition.- 2.7.3. First adjustment of the naive defenition: structural and functional characteristics of drugs.- 2.7.4. Second adjustment of the naive defenition: disease characteristics.- 2.7.5. The improvement of toxic effects of drugs: positive and negative aspects and their judgment.- 2.7.6. Conclusions.- 3.Experimental and therapeutic profiling in drug innovation: the early history of the beta blockers.- 3.1. Introduction.- 3.2. Historical overview of the development of the beta blockers.- 3.3. From Dale to Ahlquist: a new methodology in pharmacology.- 3.4. Change in the concepts of agonist and antagonist.- 3.5. Experimental and therapeutic profiling in drug innovation.- 3.5.1. Cardiac arrhythmias.- 3.5.2. Angina pectoris.- 3.6. Conclusions.- 4. Industrial research and beta blockade.- 4.1. Introduction.- 4.2. Beta blocker research at Imperial Chemical Industries (ICI).- 4.2.1. The early phase.- 4.2.2. The birth of pronethalol.- 4.2.3. The demise of pronethalol.- 4.2.4. The development of propranolol.- 4.2.4.1. A "clean" drug.- 4.2.4.2. The rapid expansion of a successful drug.- 4.2.4.3. Endangered drug.- 4.2.5. The development of practolol.- 4.2.5.1. Practolol: a tool in industrial research.- 4.2.5.2. Selectivity in industrial and academic research.- 4.2.5.3. The therapeutic interest.- 4.3. The beta blocker project of Eli Lilly & Co..- 4.4. The beta blocker project of Mead Johnson.- 4.5. The beta blocker project of AB Hassle.- 4.5.1. The early phase.- 4.5.2. Intrinsic sympathomimetic activity of alprenolol.- 4.5.3. The profiling of alprenolol.- 4.5.4. Selective beta blockade.- 4.6. The beta blocker project at CIBA.- 4.7. Conclusions.- 5. Verapamil: dying drug or sleeping beauty?.- 5.1 Introduction.- 5.2 The early history of verapamil.- 5.3 Verapamil: a coronary vasodilator?.- 5.4 Verapamil: a beta blocker?.- 5.5. Verapamil: a calcium antagonist! - The elucidation of verapamil's mechanism of action by Fleckenstein.- 5.6. Citation analysis of the concept of calcium antagonism elaborated by Fleckenstein.- 5.7. The application of the theory of drug and disease profiles.- 5.7.1. Changing views on the

This book provides comprehensive reviews on our most recent understanding of the molecular and cellular mechanisms underlying atherosclerosis and calcific aortic valve disease (CAVD) as visualized in animal models and patients using optical molecular imaging, PET-CT, ultrasound and MRI. In addition to presenting up-to-date information on the multimodality imaging of specific pro-inflammatory or pro-calcification pathways in atherosclerosis and CAVD, the book addresses the intriguing issue of whether cardiovascular calcification is an inflammatory disease, as has been recently supported by several preclinical and clinical imaging studies. In order to familiarize researchers and clinicians from other specialties with the basic mechanisms involved, chapters on the fundamental pathobiology of atherosclerosis and CAVD are also included. The imaging chapters, written by some of the foremost investigators in the field, are so organized as to reveal the nature of the involved mechanisms as disease progresses.

In recent years there have been major advances in the fields of cardiovascular nuclear medicine and cardiac magnetic resonance imaging. In nuclear cardiology more adequate tomographic systems have been designed for routine cardiac use, as well as new or improved quatitative analytic software packages both for planar and tomographic studies implemented on modern state-of-the-art workstations. In addition, artificial intelligence techniques are being applied to these images in attempts to interpret the nuclear studies in a more objective and reproductive manner. Various new radiotracers have been developed, such as antimyosin, labelled isonitriles, metabolic compounds, etcetera. Furthermore, alternative stress testing with dipyridamole and dobutamine has received much attention in clinical cardiac practice. Magnetic resonance imaging is a relative newcomer in cardiology and has already shown its merits, not only for anatomical information but increasingly for the functional aspects of cardiac performance.

The past 50 years have witnessed a breathtaking evolution in the approaches to the patient with an acute ST elevation myocardial infarction. In the 1960s, the now commonplace cardiac intensive care unit was but a nascent idea. Without much to offer the patient but weeks of absolute bedrest, substantial morbidity and high rates of mortality were the norm. Just 30 years ago, seminal discoveries by DeWood and colleagues suggested that the culprit was plaque rupture with thrombosis, not progressive luminal compromise. Subsequent fibrinolyt- based strategies resulted in a halving of the mortality of acute myocardial infarction. With the introduction of balloon angioplasty in the late 1970s, a few interventional cardiologists braved the question: why not perform emergency angioplasty as a primary reperfusion strategy? Indeed, reports of successful reperfusion via balloon angioplasty appeared (mostly in local newspapers) as early as 1980. Despite being thought of as heretical by mainstream cardiology, these pioneers nonetheless persevered, proving the benefit of ''state-of-the-art'' balloon angioplasty compared with ''state-of-t- art'' thrombolytic therapy in a series of landmark trials published in the New England Journal of Medicine in March of 1993. Publication of the first edition of Primary Angioplasty in Acute Myocardial Infarction in 2002 to some extent anticipated the widespread acceptance of primary percutaneous coronary intervention as the standard of care. Since then, in all respects, the evolution of emergency percutaneous revascularization has only accelerated. The universal replacement of balloon angioplasty with stent implantation was clearly one key.

There are growing questions regarding the safety, quality, risk management, and costs of PCC teams, their training and preparedness, and their implications on the welfare of patients and families. This innovative book, authored by an international authorship, will highlight the best practices in improving survival while paving a roadmap for the expected changes in the next 10 years as healthcare undergoes major transformation and reform. An invited group of experts in the field will participate in this project to provide the timeliest and informative approaches to how to deal with this global health challenge. The book will be indispensable to all who treat pediatric cardiac disease and will provide important information about managing the risk of patients with pediatric and congenital cardiac disease in the three domains of: the analysis of outcomes, the improvement of quality, and the safety of patients.

In the last 35 years, declining deaths from heart disease have translated into 13 million lives saved and extended. Medical treatments and lifestyle changes have dealt successfully with the serious heart problems of Vice President Richard Cheney, talk show host David Letterman, Disney-ABC CEO Michael Eisner, and countless other less famous people. In the past, those with serious heart disease would have died young, but today can live long and active lives. Few families have not benefited from improvements in the way we treat and prevent heart problems, yet we often hear that poor lifestyles and the limitations of modern medicine threaten our health and well-being. Although room for improvement always remains, this book provides evidence to the contrary: we have made and continue to make tremendous progress in dealing with heart disease. In reviewing the progress being made in this crucially important area of health, Pampel and Pauley offer an optimistic view of the potential for continued improvement and for longer, healthier lives. Despite the prevalence of heart disease, deaths from this cause have declined greatly in past decades. From its peak in 1968, the heart disease mortality rate has fallen by 52% for men and 48% for women. That translates into over 13 million lives saved and extended. The lives saved are not limited to the very old. To the contrary, heart disease mortality has fallen faster among the young and middle aged.

Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 150 disorders characterized by scarring or fibrosis of the lungs. In Pulmonary Arterial Hypertension and Interstitial Lung Disease: A Clinical Guide, renowned experts provide a state-of-the-art overview of the problems seen by physicians in the clinical management of ILDs. Divided into two sections, the first part provides and update on general issues and introduces both interstitial lung disease and associated pulmonary hypertension. A detailed analysis of the pathology of the various interstitial lung diseases is also provided. The second part addresses specific categories of disease. Bronchiolitis, hypersensitivity pneumonitis, and other conditions are covered, and the use of inspiratory and expiratory high resolution CT scan is discussed as well. This important new text is an invaluable resource for the practicing physician who must be aware of the broad and troubling manifestations of interstitial lung disease.

Together, the volumes in this series present all of the data needed at various length scales for a multidisciplinary approach to modeling and simulation of flows in the cardiovascular and ventilatory systems, especially multiscale modeling and coupled simulations. The cardiovascular and respiratory systems are tightly coupled, as their primary function is to supply oxygen to and remove carbon dioxide from the body's cells. Because physiological conduits have deformable and reactive walls, macroscopic flow behavior and prediction must be coupled to nano- and microscopic events in a corrector scheme of regulated mechanism. Therefore, investigation of flows of blood and air in anatomical conduits requires an understanding of the biology, chemistry, and physics of these systems together with the mathematical tools to describe their functioning in quantitative terms. The present volume focuses on macroscopic aspects of the cardiovascular and respiratory systems in pathological conditions, i.e., diseases of the cardiac pump, blood vessels, and airways, as well as their treatments. Only diseases that have a mechanical origin or are associated with mechanical disorders are covered. Local flow disturbances can trigger pathophysiological processes or, conversely, result from diseases of conduit walls or their environment. The ability to model these phenomena is essential to the development and manufacturing of medical devices, which incorporate a stage of numerical tests in addition to experimental procedures.

This book presents a collection of expert reviews on different subcellular compartments of the cardiomyocyte, addressing fundamental questions such as how these compartments are assembled during development, how they are changed in and by disease and which signaling pathways have been implicated in these processes so far. As such, it offers the first overview of the cell biology of heart disease of its kind, addressing the needs of cell biology students specializing in vascular and cardiac biology, as well as those of cardiologists and researchers in the field of cell biology.

Heart failure incidence increases with age and because the oldest segment of the population in Western countries is the fastest growing, the prevalence of heart failure is expected to increase. Understanding the signs and symptoms of heart failure is therefore of increasing necessity for physicians. Hemodynamic monitoring provides data on blood flow and pressure to assist physicians in determining the status of the patient's heart and in managing heart failure. This issue provides a detailed picture of the various options for assessing hemodynamics, including clinical assessment, echocardiography, transthoracic impedance cardiography, pulmonary artery catheters, B-type natriuretic peptide levels, and implantable devices.

Atrial fibrillation (AF) is the most common sustained arrhythmia, affecting approximately 2.3 million people in the US. One of the most serious side effects of AF is embolic stroke. Technology developed in the last 10 years has made AF treatable and potentially curable. This issue discusses many of the clinical issues in the management of AF, including cardioversion, anticoagulation, and ablation. Also included are current guidelines for treatment and a view of the future.

This book synthesizes the major research advances in molecular, biochemical and translational aspects of aging and heart failure over the last four decades and addresses future directions in management and drug discovery. It presents clinical issues and molecular mechanisms related to heart failure, including the changing demographics in the aging population with heart failure; hypertension and prevention of diastolic heart failure in the aging population; polypharmacy and adverse drug reactions in the aging population with heart failure; changes in the heart that accompany advancing age from humans to molecules; aging-associated alterations in myocardial inflammation and fibrosis and aging-related changes in mitochondrial function and implications for heart failure therapy. The book succinctly summarizes the large volume of data on these key topics and highlights novel pathways that need to be explored. Featuring contributions from leading clinician-scientists, Aging and Heart Failure: Mechanisms and Management is an authoritative resource on the major clinical issues in heart failure therapy in the elderly for cardiologists, gerontologists and internists.

Understanding how angiogenesis "works" and how to control it will have massive implications on the management, treatments, and ultimately the prevention of many common (and not so common) diseases. Angiogenesis is the growth of new blood vessels and is an important natural process in the body. A healthy body maintains a perfect balance of angiogenesis modulators. In many serious disease states, however, the body loses control over angiogenesis. Diseases that are angiogenesis-dependent result when blood vessels either grow excessively or insufficiently.
* Tried-and-tested techniques written by researchers that developed them, used them, and brought them to fruition
* Provides the "builder's manual" for essential techniques--a one-stop shop that eliminates needless searching among untested techniques
* Includes step-by-step methods for understanding the cell and molecular basis of wound healing, vascular integrin signaling, mechanical signaling in blood vessels, and vascular proteomics

Angiogenesis is the growth of new blood vessels and is an important natural process in the body. A healthy body maintains a perfect balance of angiogenesis modulators. In many serious disease states, however, the body loses control over angiogenesis. Diseases that are angiogenesis-dependent result when blood vessels either grow excessively or insufficiently. Understanding how angiogenesis "works" and how to control it, will have massive implications on the management, treatments, and ultimately the prevention of many common (and not so common) diseases.
Angiogenesis cuts across virtually every discipline. The Angiogenesis Foundation identified angiogenesis as a "common denominator" in our most serious diseases. Excessive angiogenesis occurs in diseases such as cancer, diabetic blindness, age-related macular degeneration, rheumatoid arthritis, psoriasis, and many other conditions. Insufficient angiogenesis occurs in diseases such as coronary artery disease, stroke, and delayed wound healing.

* Tried-and-tested techniques written by researchers that developed them, used them, and brought them to fruition.
* Provides the "builder's manual" for essential techniques. This is a one-stop shop that eliminates needless searching among untested techniques.
* Includes step-by-step methods for understanding the cell and molecular basis of wound healing, vascular integrin signaling, mechanical signaling in blood vessels, and vascular proteomics

Angiogenesis is the growth of new blood vessels and is an important natural process in the body. A healthy body maintains a perfect balance of angiogenesis modulators. In many serious disease states, however, the body loses control over antiogenesis. Diseases that are angiogensis-dependent result when blood vessels either grow excessively or insufficiently.
* Tried-and-tested techniques written by researchers that developed them, used them, and brought them to fruition
* Provides the "builder's manual" for essential techniques--a one-stop shop that eliminates needless searching among untested techniques
* Includes step-by-step methods for understanding the cell and molecular basis of wound healing, vascular integrin signaling, mechanical signaling in blood vessels, and vascular proteomics

Angiogenesis is a multi-stage process that drives the generation of new blood and lymphatic vessels from pre-existing ones. It is highly active during embryogenesis, largely inactive during adulthood but reactivated during wound healing and under a number of pathological conditions including cancer and ocular diseases. In addition to endothelial cells, which line the walls of the vessels, several other cell types (pericytes, macrophages, progenitor cells ) also contribute to angiogenesis. A number of signaling pathways are activated and very finely tune the delicate morphogenetic events that ultimately lead to the formation of stable blood proof neovessels.

This book reviews recent advances in our understanding of the molecular and cellular mechanisms of angiogenesis, with a focus on how to integrate these observations into the context of developmental, post-natal and pathological neovascularization.

The book was published under the auspices of the French Angiogenesis Society. Most contributors are prominent members of this Society or international researchers who have actively contributed to the Annual Meetings of the Society."

This comprehensive reference textbook examines in detail physiological and pathophysiological aspects of the cardiovascular system and cardiovascular disease in the sporting population. In the first part of the book, the non-invasive and invasive diagnostic techniques employed in cardiology are systematically reviewed, with explanation of their indications and clinical utility. The second, more extensive part is devoted to clinical cardiology and covers the great majority of cardiological problems encountered among athletes and other sportsmen and -women. Syncope, cardiac arrhythmias, and sudden cardiac death are extensively addressed, and guidance is provided on sports practice for individuals with different forms of heart disease. Cardiologic rehabilitation is discussed, and attention is also paid to the legal implications of diagnosed or unsuspected cardiovascular diseases for sportspeople. Sports Cardiology will be an invaluable resource for trainee and experienced health care professionals, including in particular cardiologists and sports medicine physicians. It will provide the knowledge required in order to make critical decisions regarding eligibility, thereby preventing tragic events and especially sudden death -- the most devastating occurrence in sport.

Written by an eminent cardiovascular physiologist with a strong track record in dealing with issues related to exercise and environmental physiology, this text covers cardiovascular function from the exercise and human physiologist's viewpoint. It provides a solid foundation of knowledge of how the cardiovascular system responds and adapts to the challenges of exercise and environmental change, and analyses the practicalities of measuring cardiovascular parameters in normal human subjects. Case studies in exercise physiology throughout text. Open-ended questions at end of each chapter encourage students to explore common situations facing exercise and human physiologists. Bibliography at end of each chapter directs students to further reading resources. Summaries at start of each chapter and multiple choice questions with explanatory answers at end of book aid revision and help students test their knowledge.

This volume is the fourth in a series on quantitative coronary arteriography (QCA) published over the last seven years. Every two years the advances in this exciting field are presented by their leading experts. There is a significant growth in this field which has translated into the increasing sizes of the volumes published over the years. In addition to covering the developments in the more traditional items such as QCA and other modalities, and coronary blood flow and flow reserve, the following subjects have been emphasized in this particular volume: quality control in QCA; QCA in the major regression/progression trials; QCA in the major restenoisis studies; QCA after recanalization techniques; and QCA and infracoronary prostheses. In addition, an extensive overview is given of ZCA equipment and technical requirements. The book provides a comprehensive, overview for all clinicians and physicists actively involved or otherwise interested in the developments in quantitative coronary arteriography.

Experimental and clinical evidence supports the view that the activation of the renin angiotensin aldosterone system is involved in cardiovascular pathology including hypertension, heart failure, myocardial ischemia, and atherosclerosis. The present volume describes the intricacies involved in these processes, including the in?uence of prorenin/renin, angiotensin II, angiotensin (1-7), and aldosterone on cardiac and vascular functions as well as their involvement in the generation of cardiovascular diseases. Fundamental aspects like intracellular signaling, regulation of cell volume in the failing heart, and the presence of an intracrine renin angiotensin system are discussed. Moreover, the role of the mineralocorticoid receptor as an important c- ponent of the intracrine renin angiotensin system and as a regulator of extracellular action of angiotensin II is described, reinforcing the view that aldosterone inhibitors are helpful in the treatment of heart failure and hypertension. Let us hope the imp- tant topics included here motivate basic and clinical investigators and contribute to the development of new therapeutic approaches for cardiovascular diseases. We want to thank the distinguished authors and Humana Press for the opportunity to publish this important book. Walmor C. DeMello Edward Frohlich v Contents 1 Systemic Versus Local Renin Angiotensin Systems. An Overview ...1 Walmor C. DeMello and Richard N. Re 2 Clinical Import of the Local Renin Angiotensin Aldosterone Systems ...7 Edward D. Frohlich 3 Renin, Prorenin, and the (Pro)Renin Receptor ...15 Genevieve Nguyen and Aurelie Contrepas 4 Local Renin Angiotensin Systems in the Cardiovascular System ...25 Richard N.

This book presents the latest findings in the field of research of mechanosensitivity and mechanotransduction in different cells and tissues. Mechanosensitivity and mechanotransduction of the heart and vascular cells, in the lung, in bone and joint tissues, in sensor systems and in blood cells are described in detail. This Volume focuses on molecular mechanisms of mechanosensitivity and mechanotransduction via cytoskeleton. Integrin-mediated mechanotransduction, the role of actin cytoskeleton and the role of other cytoskeletal elements are discussed. It contains a detailed description of several stretch-induced signaling cascades with multiple levels of crosstalk between different pathways. It contains a description of the role of nitric oxide in regulation of cardiac activity and in regulation of mechanically gated channels in the heart. In the heart mechanical signals are propagated into the intracellular space primarily via integrin-linked complexes, and are subsequently transmitted from cell to cell via paracrine signaling. Biochemical signals derived from mechanical stimuli activate both acute phosphorylation of signaling cascades, such as in the PI3K, FAK, and ILK pathways, and long-term morphological modii cations via intracellular cytoskeletal reorganization and extracellular matrix remodelling. Cellular and molecular effects of mechanical stretch on vascular cells are also discussed. This Volume highlights the role of mechanotransduction in the lung, in bone and joint tissues. For the first time mechanosensitivity and mechanotransduction in blood cells are discussed. It contains new insights into mechanosensitive K+ channels functioning in mouse B lymphocytes. This book is a unique collection of reviews outlining current knowledge and future developments in this rapidly growing field. Currently, investigations of the molecular mechanisms of mechanosensitivity and mechanotransduction are focused on several issues. The majority of studies investigate intracellular signaling pathways. Knowledge of the mechanisms which underlie these processes is necessary for understanding of the normal functioning of different organs and tissues and allows to predict changes, which arise due to alterations of their environment. Possibly such knowledge will allow the development of new methods of artificial intervention and therapies. This book brings up the problem closer to the experts in related medical and biological sciences as well as practicing doctors besides just presenting the latest achievements in the field.

Cardiovascular MR imaging has become a robust, clinically useful mod- ity, and the rapid pace of innovation and important information it conveys have attracted many students whose goal is to become adept practitioners. In turn, many excellent textbooks have been written to aid this process. These books are necessary and useful in helping the student learn the underlying pulse sequences used in CMR, as well as the imaging findings in a variety of disorders. However, one of the difficulties inherent in learning CMR from a book is that the printed format is not the ideal medium to d- play the dynamic imaging that comprises a typical CMR case. For instance, it may be difficult to perceive focal areas of wall motion abnormality on serial static pictures, but these abnormalities are often easily seen on cine loops. One might say that trying to learn CMR solely from a standard textbook with illustrations is like trying to learn to drive by looking at snapshots obtained through the windshield of a moving car. The learner needs to see the cardiac motion and decide if it is normal or abnormal; he or she needs to be in the driver's seat. An additional limitation of the ava- able textbooks on CMR is that while they often have superb illustrations of abnormal findings, these images have been preselected.

This book focuses on how ventricular assist devices (VADs) can help provide destination therapy for patients with terminal heart failure, one of the most serious diseases in the world today because of the tremendous number of patients, the high mortality rate, and the cost of care. One means of providing cardiological support for patients suffering from heart failure is with VADs, and more than 10,000 patients worldwide have now been implanted with these devices. Half of them already have lived more than one year, and 2,000 patients more than two years, after surgery. This improved survival means that we have reached a point where VADs can be used for destination therapy, not just for bridge-to-recovery or bridge-to-transplant. In view of the increasing number of patients with advanced-stage heart failure and the availability and longevity of transplanted hearts, VADs can solve many problems. In addition to providing information about the devices themselves, this book includes vital guidelines on long-term management and support of VAD-implanted patients' everyday lives.

The present book reveals the importance of preventive medicine in cardiology and public health, addressing the lack of a broad discussion of this topic in the current literature. It examines the most important risk factors for different cardiovascular diseases, discussing them in detail from a clinical standpoint and presenting important information from a preventive medicine perspective. Further, specific chapters discuss the burden of cardiologic risk factors in special contexts, such as in women, child and adolescents, and in low-income populations. Lastly, a number of conditions that are often overlooked in terms of their cardiological impact are discussed, such as Chagas disease, rheumatic cardiomyopathy and post-traumatic stress disorder. Cardiovascular diseases are still the major cause of death in the world, even though they are considered preventable clinical conditions. The increased prevalence of some risk factors for cardiovascular diseases is an important concern for cardiologists around the world. On the other hand, primary prevention programs have proven their efficacy concerning some known and treatable risk factors, such as with hypercholesterolemia, hypertension, diabetes and smoking, but still need to be made more of a priority in public health. Prevention of Cardiovascular Diseases is a book intended for multi-disciplinary audience and aimed for all professionals who are willing to face the challenge of cardiovascular prevention